KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Current Assets: 2009-2024

Historic Current Assets for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $18.7 billion.

  • Regeneron Pharmaceuticals' Current Assets fell 7.00% to $18.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 billion, marking a year-over-year decrease of 7.00%. This contributed to the annual value of $18.7 billion for FY2024, which is 4.20% down from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Current Assets of $18.7 billion as of FY2024, which was down 4.20% from $19.5 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' 5-year Current Assets high stood at $19.5 billion for FY2023, and its period low was $9.8 billion during FY2020.
  • Its 3-year average for Current Assets is $18.0 billion, with a median of $18.7 billion in 2024.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Current Assets soared by 43.31% in 2021 and then decreased by 4.20% in 2024.
  • Over the past 5 years, Regeneron Pharmaceuticals' Current Assets (Yearly) stood at $9.8 billion in 2020, then soared by 43.31% to $14.0 billion in 2021, then climbed by 13.34% to $15.9 billion in 2022, then increased by 22.63% to $19.5 billion in 2023, then fell by 4.20% to $18.7 billion in 2024.